ATOS

Atossa Therapeutics Inc

Add to Watchlist

Advanced Chart

0.792

+0.016(2.061%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.792

Open

0.792

VWAP

0.79

Vol

763.00

Mkt Cap

100.30M

Low

0.792

Amount

604.30

EV/EBITDA(TTM)

Total Shares

125.76M

42.44M

EV/OCF(TTM)

P/S(TTM)

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.063

+5.55%

-0.063

+26.66%

-0.060

+20%

Estimates Revision

The market is revising No Change the revenue expectations for Atossa Therapeutics, Inc. (ATOS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -19.48%.

EPS Estimates for FY2025

Revise Upward

+2.22%

In Past 3 Month

Stock Price

Go Down

-19.48%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast ATOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATOS is 5.63 USD with a low forecast of 4.00 USD and a high forecast of 7.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.792

Low

4.00

Averages

5.63

High

7.50

Current: 0.792

Low

4.00

Averages

5.63

High

7.50

Craig-Hallum

NULL

Buy

initiated

2025-06-05

Reason

Craig-Hallum

Price Target

2025-06-05

initiated

NULL

Buy

Reason

Craig-Hallum initiated coverage of Atossa Therapeutics with a Buy rating and $4 price target.

Craig-Hallum

Buy

initiated

2025-06-05

Reason

Craig-Hallum

Price Target

2025-06-05

initiated

Buy

Reason

As previously reported, Craig-Hallum initiated coverage of Atossa Therapeutics with a Buy rating and $4 price target. The firm points out that Z-endoxifen is a novel and potent SERM that can treat all stages of breast cancer. As the primary therapeutic metabolite of tamoxifen, Z-endoxifen is de-risked and has demonstrated differentiated efficacy and an advantageous safety profile in multiple clinical studies, Craig-Hallum argues, adding that Z-endoxifen development is focused on metastatic breast cancer, which offers the fastest path to market and can strategically support future expansion to early disease settings. The most notable opportunity is prevention, where Z-endoxifen's ability to avoid menopausal-like side effects can support uptake in a large TAM of over 10M women at high-risk of developing breast cancer in the U.S. The firm believes Atossa is undervalued and sees opportunity for share appreciation as Z-endoxifen gains further validation with readouts from neoadjuvant studies expected next year and design details for a Phase III metastatic breast cancer study and initiation expected by year-end 2025.

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$7 → $7.25

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$7 → $7.25

2025-04-21

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

2025-03-26

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

2025-03-26

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

2025-03-12

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

2025-03-12

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

2025-01-30

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

2025-01-30

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Atossa Therapeutics Inc (ATOS.O) is -3.15, compared to its 5-year average forward P/E of -6.43. For a more detailed relative valuation and DCF analysis to assess Atossa Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.43

Current PE

-3.15

Overvalued PE

-0.04

Undervalued PE

-12.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00